David Hui1, Rony Dev, Eduardo Bruera. 1. Department of Palliative Care and Rehabilitation Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abstract
PURPOSE OF REVIEW: Delirium is the most common and distressing neuropsychiatric syndrome in cancer patients. Few evidence-based treatment options are available due to the paucity of high quality of studies. In this review, we shall examine the literature on the use of neuroleptics to treat delirium in patients with advanced cancer. Specifically, we will discuss the randomized controlled trials that examined neuroleptics in the front line setting, and studies that explore second-line options for patients with persistent agitation. RECENT FINDINGS: Contemporary management of delirium includes identification and management of any potentially reversible causes, coupled with nonpharmacological approaches. For patients who do not respond adequately to these measures, pharmacologic measures may be required. Haloperidol is often recommended as the first-line treatment option, and other neuroleptics such as olanzapine, risperidone, and quetiapine represent potential alternatives. For patients with persistent delirium despite first-line neuroleptics, the treatment strategies include escalating the dose of the same neuroleptic, rotation to another neuroleptic, or combination therapy (i.e., the addition of a second neuroleptic or other agent). We will discuss the advantages and disadvantages of each approach, and the available evidence to support each strategy. SUMMARY: Adequately powered, randomized trials involving proper control interventions are urgently needed to define the optimal treatment strategies for delirium in the oncology setting.
PURPOSE OF REVIEW: Delirium is the most common and distressing neuropsychiatric syndrome in cancerpatients. Few evidence-based treatment options are available due to the paucity of high quality of studies. In this review, we shall examine the literature on the use of neuroleptics to treat delirium in patients with advanced cancer. Specifically, we will discuss the randomized controlled trials that examined neuroleptics in the front line setting, and studies that explore second-line options for patients with persistent agitation. RECENT FINDINGS: Contemporary management of delirium includes identification and management of any potentially reversible causes, coupled with nonpharmacological approaches. For patients who do not respond adequately to these measures, pharmacologic measures may be required. Haloperidol is often recommended as the first-line treatment option, and other neuroleptics such as olanzapine, risperidone, and quetiapine represent potential alternatives. For patients with persistent delirium despite first-line neuroleptics, the treatment strategies include escalating the dose of the same neuroleptic, rotation to another neuroleptic, or combination therapy (i.e., the addition of a second neuroleptic or other agent). We will discuss the advantages and disadvantages of each approach, and the available evidence to support each strategy. SUMMARY: Adequately powered, randomized trials involving proper control interventions are urgently needed to define the optimal treatment strategies for delirium in the oncology setting.
Authors: A Caraceni; O Nanni; M Maltoni; L Piva; M Indelli; E Arnoldi; M Monti; L Montanari; D Amadori; F De Conno Journal: Cancer Date: 2000-09-01 Impact factor: 6.860
Authors: Pratik P Pandharipande; Brenda T Pun; Daniel L Herr; Mervyn Maze; Timothy D Girard; Russell R Miller; Ayumi K Shintani; Jennifer L Thompson; James C Jackson; Stephen A Deppen; Renee A Stiles; Robert S Dittus; Gordon R Bernard; E Wesley Ely Journal: JAMA Date: 2007-12-12 Impact factor: 56.272
Authors: Tayyeb A Tahir; Eamonn Eeles; Venugopal Karapareddy; Prem Muthuvelu; Sian Chapple; Bethan Phillips; Toyin Adyemo; Daniel Farewell; Jonathan I Bisson Journal: J Psychosom Res Date: 2010-06-23 Impact factor: 3.006
Authors: Maurice J D L van der Vorst; Elisabeth C W Neefjes; Manon S A Boddaert; Bea A T T Verdegaal; Aart Beeker; Saskia C C Teunissen; Aartjan T F Beekman; Janneke A Wilschut; Johannes Berkhof; Wouter W A Zuurmond; Henk M W Verheul Journal: Oncologist Date: 2019-12-04
Authors: Edith Monreal-Carrillo; Silvia Allende-Pérez; David Hui; Maria-Fernanda García-Salamanca; Eduardo Bruera; Emma Verástegui Journal: Support Care Cancer Date: 2017-04-29 Impact factor: 3.603